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Validation Study for the Korean Version of Fear of Cancer 
Recurrence Inventory
Fear of cancer recurrence (FCR) is one of the most prevalent unmet psychosocial needs. 
This study aimed to confirm the cultural equivalence, reliability, and validity of the Korean 
version of Fear of Cancer Recurrence Inventory (K-FCRI). We conducted a forward–
backward translation of the English version FCRI to Korean version through meticulous 
process including transcultural equivalence test. The psychometric property of the K-FCRI 
was then validated in 444 survivors from cancers at various sites. The Korean translation 
was accepted well by participants. There was a good cultural equivalence between the 
Korean version and the English version of FCRI. Confirmatory factor analysis supported the 
original seven-factor structure with slightly insufficient level of goodness-of-fit indices 
(comparative fit index = 0.900, non-normed fit index = 0.893, root mean square error of 
approximation = 0.060). The K-FCRI had high internal consistency (α = 0.85 for total scale 
and α = 0.77–0.87 for subscales) and test-retest reliability (r = 0.90 for total scale and 
r = 0.54–0.84 for subscales). The K-FCRI had significant correlations with the Korean 
version of Fear of Progression Questionnaire, European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire Version 3.0, Hospital Anxiety and 
Depression Scale, and Fatigue Severity Score, supporting the good construct validity and 
psychometric properties of K-FCRI. The K-FCRI was confirmed as a valid and reliable 
psychometric test for measuring FCR of Korean survivors from cancers at various sites.
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INTRODUCTION
Fear of cancer recurrence (FCR) is defined as the fear that can-
cer might return or progress in the same region or in another 
part of the body (1,2). People who have been diagnosed with 
cancer commonly suffer from various degrees of FCR. A study 
has reported that over 30% of ovarian cancer patients have ex-
perienced worry about cancer recurrence at least once a week, 
even after surviving for more than 2 years after completing can-
cer treatment (3). About 56% of breast cancer survivors have 
experienced moderate to severe FCR in another study (4). FCR 
is one of the most prevalent unmet psychosocial needs. It might 
be associated with psychological distress, functioning impair-
ments, and increased use of health care resources (5,6). There-
fore, evaluation of FCR seems essential for the care of cancer 
survivors. However, relatively few measures are available based 
on empirically supported theory of FCR (7).
 Fear of Cancer Recurrence Inventory (FCRI), one of the stron-
gest psychometrical tools that measures FCR for heterogeneous 
cancer populations, has been developed based on cognitive-
behavioral conceptualization of FCR (7,8). It contains 42 items 
evaluating seven FCR components (triggers, severity, psycho-
logical distress, functioning impairments, insight, reassurance, 
and coping strategies). The original French version of FCRI was 
developed by Simard and Savard (8) using 600 French Canadi-
ans who survived breast, colon, prostate, or lung cancer. It has 
excellent level of internal consistency, reliability, and construct-
ed validity (8). After that, an English version of FCRI has been 
validated (2).
 In Korea, the 5-year survival rate of cancer patients was in-
creased from 53.8% during 2001–2005 to 69.4% during 2008–
2013, resulting in about 1,370,049 cancer survivors in 2013 (9). 
Several studies have found that the prevalence of psychological 
problem is substantially high in Korean cancer survivors (10-
12). Therefore, the need for an instrument that adopts multi-di-
mensional approach to assess FCR of Korean cancer survivors 
is increasing. To the best of our knowledge, psychometrical in-
strument that encompasses comprehensive aspects of FCR of 
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Koreans is currently unavailable. Therefore, the objective of the 
present study was to determine the cross-cultural equivalence 
of the Korean version of FCRI (K-FCRI) and examine its reliabil-
ity and validity of K-FCRI using psychometric properties. 
MATERIALS AND METHODS
We conducted the translation and validation of the K-FCRI thr-
ough the following steps: 1) performing forward–backward trans-
lation of English version FCRI and pilot test, 2) establishing cross-
cultural equivalence using a bilingual (both English and Korea) 
sample, and 3) measuring the psychometric properties in a large 
sample of Korean cancer survivors.
Translation and pilot test
The FCRI is a multidimensional questionnaire composed of 
seven subscale components of FCR: potential stimuli activating 
FCR (triggers), presence and severity of intrusive thoughts as-
sociated with FCR (severity), emotional disturbance associated 
with FCR (psychological distress), impact of FCR on important 
areas of functioning (functional impairments), self-criticism to-
ward FCR intensity (insight), reassurance seeking such as thor-
ough self-examination or repeated medical consultations (re-
assurance), and other strategies to cope with FCR (coping strat-
egies) (8). Each item is rated on a Likert scale ranging from zero 
(‘not at all’ or ‘never’) to four (‘a great deal’ or ‘all the time’). A 
subscale score can be calculated for each subscale component. 
The total score is then calculated based on the scores of each 
subscale. Considering that the question for item 13 (“I believe 
that I am cured and the cancer will not come back”) is addressed 
in opposite direction of other questions, the response scale to 
item 13 is reversely put in the calculation of total score. Higher 
summary score of FCRI indicates higher levels of FCR. In addi-
tion, the severity subscale of the FCRI (also referred to as FCRI-
short form) has an empirically validated cutoff score (≥ 13 points) 
for screening clinically significant level of FCR (13). Cronbach’s 
alpha value for each seven subscales has been reported as fol-
lows in a previous validation study (8): trigger, α = 0.90; severity, 
α = 0.89, psychological distress, α = 0.86; functioning impair-
ments, α = 0.91; insight, α = 0.80; reassurance, α = 0.75; and cop-
ing strategies, α = 0.89.
 Initial translation of the FCRI from English version to Korean 
was done by a panel composed of three medical experts (one 
psychologist and two family physicians) who can speak both 
English and Korean fluently. Another bilingual psychologist 
who was blinded to the English version of FCRI backward trans-
lated the K-FCRI into English. A certified simultaneous Korean-
English interpreter assessed the backward-translated English 
version FCRI as having maintained the semantics and mean-
ings of the English version of FCRI.
 Using the first-translated K-FCRI, a pilot test was conducted 
in 13 participants, including three cancer patients (breast, stom-
ach, and thyroid), two patients without cancer, six physicians, 
and two nurses. All participating physicians and nurses had ex-
perience in cancer patient management. For the pilot test, the 
K-FCRI was self-administered to the 13 participants. A face-to-
face interview was then performed by a well-trained research 
assistant to ask them whether any items of questions were con-
fusing or difficult to answer. The first-translated K-FCRI was 
then revised accordingly to develop the final Korean version by 
the two initial translators considering the feedback and pro-
posed changes based on the pilot test. The final Korean version 
was re-pilot tested in another five cancer patients (breast, two 
stomach, thyroid, and colon). They confirmed that the instruc-
tions, questions, and response options of the final K-FCRI could 
be clearly understood.
Cross-cultural validity and reliability
Thirty-two bilinguals composed of six cancer patients, eight 
nurses, and 18 physicians assessed the cultural equivalence of 
the K-FCRI and the original English versions FCRI. The mean 
score of these bilingual evaluators in assessing the level of flu-
ency in both Korean and English was 6.1 in a self-rated 10-point 
scale (0 point: not at all to 10 point: perfectly).
 We evaluated the language, similarity, and interpretability 
between the English version FCRI and the K-FCRI using coun-
terbalanced design (13,14), for which participants were ran-
domly assigned to begin with either the Korean version or with 
the original English version. Comparability of language refers to 
the formal similarity of words, phrases, and sentences. Similari-
ty of interpretability refers to the degree to which the two ver-
sions engender the same response even though the wording is 
not the same. Similarity was quantified by Likert scale ranging 
from one (extremely comparable/extremely similar) to seven 
(not at all comparable/not at all similar). Question items acquir-
ing a mean score of > 3 in any category or between 2.5 and 3 in 
interpretability were considered problematic and reviewed for 
possible correction (15). In our study, further correction was 
unnecessary because the mean scores for the comparability of 
language and similarity of interpretability were 1.34 and 1.49, 
respectively. Therefore, cultural equivalence of the FCRI between 
the Korean version and the English version was confirmed. To 
estimate the test-retest reliability of K-FCRI, we repeatedly ad-
ministered it to 62 participants (14.0%) on two occasions with 
mean interval of 206 days (range, 25–444 days).
Measurement of psychometric properties
A self-administered questionnaire consisting of the K-FCRI and 
other instruments selected for validation of psychometric prop-
erty of FCRI was given to 444 study participants. A trained re-
search assistant supplemented the incompletely answered ques-
tions through additional face-to-face interview if necessary.
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 We assessed the psychometric properties of the K-FCRI in 
long-term cancer survivors who had visited cancer survivorship 
clinic for routine surveillance or care for health problems from 
September 2014 to December 2015. Of 603 cancer survivors 
who were contacted, 156 (25.9%) refused to participate in our 
study. The most common reasons for refusal were “too busy to 
complete the questionnaire” or “feel uncomfortable to be in-
volved in a research.” Demographic characteristics of study par-
ticipants were compared to those of nonparticipants using t-
test or χ2 test. Although non-participants had slightly different 
distribution in age and cancer sites (P < 0.010) compared to 
participants, there was no significant difference in the time lapse 
since cancer diagnosis, distribution of sex, or treatment modal-
ity (Supplementary Table 1). Among 447 cancer survivors who 
provided written informed consent form, we excluded those who 
had missing data for more than 50% of question items (n = 1), 
answering with ‘0’ to all questions (n = 2) including one item 
that was reverse scored (item 13). Finally, data from 444 cancer 
survivors were included in our final analysis.
 We selected four Korean version of instruments which have 
been previously validated for measuring psychological distress 
in Korean patients with cancer or other chronic diseases. They 
are Fear of Progression Questionnaire (FoP-Q), European Orga-
nization for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC QLQ-C30, version 3.0), Hospital Anxi-
ety and Depression Scale (HADS), and Fatigue Severity Score 
(FSS).
 The FoP-Q consists of 43 statements regarding various con-
cerns related to disease progression and coping with these con-
cerns categorized into five subscales: affective reactions (13 items), 
partnership/family (7 items), occupation (7 items), loss of au-
tonomy (7 items), and coping (9 items) (14). A five-point Likert 
scale was used for checking responses from 1 (never) to 5 (very 
often). It provides two total scores: one for FoP and the other for 
coping (14). In a study for validating the Korean version of FoP-
Q, the Cronbach’s alpha coefficient has been reported to be 0.92 
for FoP total scale, 0.90 for affective reactions, 0.73 for partner-
ship/family, 0.87 for occupation, 0.84 for loss of autonomy, and 
0.68 for coping (14).
 The 30-item questionnaire, EORTC QLQ-C30 was developed 
to assess health related quality of life of cancer patients, incor-
porating five functional scales (physical, cognitive, social, emo-
tional, and role), symptom scale, and global quality of life scale 
(16). The score of each scale ranges from zero to 100. Lower func-
tional score (≤ 33) indicates worse global health status and worse 
functional status while higher symptom score (≥ 66) indicates 
worse symptomatic status. The Cronbach’s alpha coefficients 
for the Korean version of EORTC QLQ-C30 have been found to 
be greater than 0.70 for most subscales in a previous validation 
study except for cognitive functioning (α = 0.60) (16).
 HADS is a 14-item questionnaire widely used to assess both 
dimensional and categorical aspects of anxiety and depression 
in cancer patients (17). Total summary score of HADS ranges 
from 0 to 21, with higher score indicating greater level of anxiety 
or depression. In a previous validation study for the Korean ver-
sion of HADS, the Cronbach’s alpha coefficient has been found 
to be 0.78 for anxiety subscale and 0.85 for depression subscale 
(18).
 FSS is a 10-item questionnaire developed to assess the effect 
of fatigue on daily activities with seven-point response scale from 
1 (strongly disagree) to 7 (strongly agree) (19). Higher score de-
notes more severe fatigue. In a previous validation study for the 
Korean version of FSS, the Cronbach’s alpha coefficient for total 
FSS is 0.935, ranging from 0.925 to 0.932 for subscales (20).
 Other measurements in this study included demographic 
and socioeconomic characteristics (marital status, education 
level, employment status, income level, religious activity) of 
participants, which were obtained using a self-administered 
questionnaire. We reviewed medical records to obtain informa-
tion about cancer such as the site and stage of cancer treatment 
modality, status of metastases at the time of primary cancer di-
agnosis, cancer recurrence, second primary cancer, and family 
history of cancer.
Statistical analysis
We evaluated the difference of total K-FCRI score between dif-
ferent cancer sites by the analysis of variance (ANOVA) with 
post-hoc comparison, after adjusting for years since diagnosis, 
sex, and cancer stage. The reliability of K-FCRI was assessed by 
internal consistency and test-retest reliability. Internal consis-
tency between items pertained to a subscale was estimated based 
on the Cronbach’s alpha coefficient. Test-retest reliability was 
assessed by estimating intra-class correlations between respons-
es to repeatedly addressed K-FCRI questionnaire on two differ-
ent occasions. Construct validity of K-FCRI was evaluated by 
estimating convergent validity, concurrent criterion validity, and 
divergent validity.
 We conducted a series of confirmatory factor analyses (CFAs) 
on the K-FCRI to assess divergent validity by examining wheth-
er the original 7-factor solution found for the English version 
FCRI could be replicated in K-FCRI (8). The tested model was 
planned with three levels following the original structure mod-
el: each of the 42 items, primary factors (7 subscales), and one 
secondary factor (FCR total score). Goodness-of-fit indices were 
used to assess the fitness of this model using chi-square likeli-
hood ratio statistic (χ2), comparative fit index (CFI), non-normed 
fit index (NNFI), and root-mean-square error of approximation 
(RMSEA). The cut-off criteria for assessing goodness-of-fit were 
≥ 0.90 for CFI, ≥ 0.95 for NNFI, and ≤ 0.06 for RMSEA (21).
 Convergence validity was assessed by estimating Pearson’s 
correlation coefficients between each subscale, between total 
summary score of K-FCRI and the score of each subscale of K-
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FCRI, and between each item and total summary score after 
correcting overlap. Concurrent criterion validity was evaluated 
by estimating Pearson’s correlation coefficients between total 
K-FCRI score and scores of the Korean version of other psycho-
metric instruments selected for this study such as FoP-Q, EORTC 
QLQ-C30, HADS, and FSS.
 CFA was performed using Mplus version 6.1 (Muthén and 
Muthén, Los Angeles, CA, USA). All other analyses were per-
formed using PASW Statistics 23.0 software (SPSS Inc., Chicago, 
IL, USA). The correlation strength was categorized according to 
the original validation study: weak (< 0.4), moderate (0.4–0.69), 
and strong (≥ 0.7) (22).
Ethics statement
Institutional Review Board (IRB) of Samsung Medical Center 
approved this study (IRB file number: SMC 2013-07-133). In-
formed consent was obtained from each participant.
RESULTS
The characteristics and score of the K-FCRI of the study popula-
tion are summarized in Table 1. The mean age and mean sur-
vival time after cancer diagnosis were 55.3 years and 6.0 years, 
respectively. Most participants were married. Approximately 
half of these participants had received college or higher level of 
education with employed status. Around three quarters of these 
participants were involved in religious activities. The mean of 
total summary score of K-FCRI was 59.4. Among subscales of K-
FCRI, the score for coping strategy was the highest, followed by 
trigger, severity, reassurance, and distress. The score for insight 
was the lowest.
 Cancer related information of participants is shown in Table 
2. The sites of primary cancer were very diverse. Stomach and 
breast cancer patients occupied more than 50% of participants. 
Earlier stages of cancer were more common. More than half of 
these participants had stage I cancer. Most (96.1%) of these par-
ticipants had undergone surgery for cancer treatment. At the 
time of primary cancer diagnosis, 1.3% had metastatic lesion. 
Among these cancer participants, 1.6% experienced recurrence 
of cancer and 3.9% already received a second primary cancer 
diagnosis. Total K-FCRI score of breast cancer patients was sig-
nificantly higher than that of stomach cancer and lung cancer 
patients.
 The findings from CFA conducted in a series of two models 
to determine factor structure of the K-FCRI and assess discrimi-
nant validity on construct level are shown in Table 3. In the ini-
tial model (model A), the goodness-of-fit indices did not fully 
meet the criteria for adequate model fit (χ2 = 2,710.283, df = 812, 
CFI = 0.853, NNFI = 0.844, RMSEA = 0.073, 90% confidence in-
terval = 0.070–0.076). In the next model (model B), modifica-
tion indices were applied to free the parameters in the error co-
variance matrix, similar to the method used by Lebel et al. (2). 
The revised model showed improvement over the initial model. 
The original seven-factor structure remained. In addition, the 
same nine covariances were found, although items 13 and 14 
were replaced by items 15 and 16. With the new adjustment, all 
goodness-of-fit indices were improved: RMSEA was improved 
from 0.073 to 0.060, CFI was improved from 0.853 to 0.900, and 
NNFI was improved from 0.844 to 0.893.
 The reliability, convergence validity, and discrimination va-
lidity of K-FCRI are shown in Table 4. Corrected item-total cor-
relations and Cronbach’s alphas met the standards of conver-
gence validity. The levels of corrected item-total correlations 
(r = 0.22 to 0.80) were neither less than 0.20 nor more than 0.80 
(23). Cronbach’s alpha values for total K-FCRI and subscales 
were 0.85 and 0.77–0.84, respectively, which were within accept-
able to good levels. Test-retest reliability assessed by the intra-
Table 1. Demographic and socioeconomic characteristics of study participants
Characteristics
Total 
(n = 444)
Men 
(n = 157)
Women 
(n = 287)
Age, yr 55.3 (10.3) 58.5 (9.5) 53.5 (10.3)
Age at cancer diagnosis, yr 49.4 (10.2) 52.6 (9.7) 47.7 (10.0)
Time since cancer diagnosis, yr 6.0 (4.2) 6.0 (3.6) 6.0 (4.5)
Marital status, %
   Married/with partner 80.9 89.8 76.0
   Single 15.7 7.0 20.9
   Unknown 3.4 3.2 3.1
Education level, %
  ≤ High school 45.1 42.0 46.9
  ≥ College degree 47.5 50.4 45.8
   Unknown 7.4 7.6 7.3
Employment, %
   Retired/unemployed 51.8 27.4 65.2
   Employed 47.5 71.3 34.5
   Unknown 0.7 1.2 0.3
Monthly household income (Korean won), %
  < 1,000,000 5.2 3.2 6.3
   1,000,000–1,990,000 12.9 13.4 12.6
   2,000,000–3,990,000 24.6 24.2 24.8
   More than 4,000,000 40.2 45.2 37.4
   Unknown 17.1 14.0 18.9
Religion
   Do not have 26.2 33.1 22.4
   Have, but no religious activity 24.6 24.8 24.5
   Irregular activity 16.7 17.2 16.4
   Regular activity 32.5 24.8 36.7
FCRI (range of score)
   Total summary score (0–168) 59.4 (24.3) 54.0 (24.2) 62.5 (23.8)
   Trigger (0–32) 13.3 (7.1) 12.3 (7.4) 13.8 (6.8)
   Severity (0–36) 12.5 (6.4) 11.7 (6.4) 12.9 (6.4)
   Psychological distress (0–16) 4.1 (3.9) 3.5 (3.6) 4.4 (4.0)
   Coping strategies (0–36) 18.5 (7.7) 16.2 (7.7) 19.8 (7.4)
   Functioning impairments (0–24) 4.9 (5.8) 4.4 (5.5) 5.1 (6.0)
   Insight (0–12) 1.4 (2.0) 1.5 (1.9) 1.3 (2.1)
   Reassurance (0–12) 4.9 (3.3) 4.4 (3.5) 5.2 (3.2)
Values are presented as mean (SD).
FCRI = Fear of Cancer Recurrence Inventory, SD = standard deviation.
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class correlation coefficient (ICC) between the responses to the 
repeatedly administered questionnaire was within reliable range: 
ICC for total K-FCRI was 0.90 (P < 0.001), ICC for subscales of 
FCRI ranged between 0.54 and 0.84 (P < 0.050). Four subscales 
(triggers, severity, psychological distress, and functioning im-
pairments) had moderate to strong levels of correlations with 
total score, whereas coping strategies, insight, and reassurance 
subscales had low to moderate correlations with total summary 
score.
 The correlations between total summary score of K-FCRI and 
scores of FoP-Q, EORTC QLQ-C30, HADS-K, and FSS are shown 
in Table 5. Total score and subscale scores of FoP-Q showed sig-
nificant positive correlations with the total score of K-FCRI. The 
correlation coefficient between K-FCRI with total score of FoP-
Q was 0.73. There were significant inverse correlations between 
total summary score of K-FCRI and the scores of EORTC QLQ-
C30 subscales. The highest correlation coefficient was found for 
emotional functioning scale. The inverse correlation between 
these tools indicated that cancer patients with high FCR might 
have poor quality of life because higher score of EORTC QLQ-
C30 reflected better status. Total summary score of K-FCRI was 
positively correlated with anxiety category of HADS. However, 
Table 2. Cancer related information of study participants according to primary cancer site
Cancer parameters Total (n = 444) Stomach (n = 173) Breast (n = 112) Lung (n = 42) Thyroid (n = 37) Other (n = 80)
Stage of primary cancer, %
   I 52.5 53.3 43.6 62.5 61.3 52.3
   II 24.9 33.3 32.7 12.5 9.7 15.9
   III & IV 19.0 13.3 14.5 25.0 29.0 25.0
   Unknown 3.6 0 9.1 0 0 6.8
Cancer treatment received, %
   Surgery 96.1 93.8 100 95.1 97.1 88.0
   Chemotherapy 41.4 37.0 70.0 35.0 0 30.1
   Radiotherapy 37.4 24.1 76.4 17.5 3.0 35.7
   Hormone therapy 1.6 - 59.6 - - -
Metastasis at diagnosis 1.3 0.6 0 2.6 3.4 2.2
Recurrence 1.6 1.3 3.0 2.8 0 0
Development of second primary cancer* 3.9 1.1 8.9 2.4 0 5.0
Family history of cancer 47.5 43.9 50.0 40.5 45.9 56.3
Total FCRI score† 59.2 (24.5) 57.2 (24.1)‡ 67.0 (24.3)‡ 52.9 (22.5)‡ 56.7 (28.0) 57.0 (23.2)
Values are presented as percentage or mean (SD).
FCRI = Fear of Cancer Recurrence Inventory, SD = standard deviation, ANOVA = analysis of variance, FCR = fear of cancer recurrence.
*Cancer sites of second primary cancer (number of cases) were thyroid (n = 10), breast (n = 3), stomach (n = 2), lung (n = 1), and ovary cancer (n = 1). †The difference among 
cancer site obtained by the ANOVA with post hoc comparison after adjusted for year since diagnosis, sex and canter stage. ‡P < 0.05, breast cancer patients had a higher level 
of FCR.
Table 3. Summary of results from CFAs for K-FCRI
Models Study χ2 df CFI NNFI RMSEA (90% CI)
Model A Simard and Savard (2009) 2,710.283 812 0.853 0.844 0.073 (0.070–0.076)
Model B Shin et al. (2017) 2,093.864 803 0.900 0.893 0.060 (0.057–0.063)
CFA = confirmatory factor analysis, K-FCRI = Korean version of Fear of Cancer Recurrence Inventory, CFI = comparative fit index, NNFI = non-normed fit index, RMSEA = root-
mean-square error of approximation, CI = confidence interval.
Table 4. Reliability and convergence validity of the K-FCRI  
Subscale components
Correlation coefficients between the subscale components Corrected  
item-total 
correlations
Cronbach’s 
alpha
ICC test- 
retestNo. items F1 F2 F3 F4 F5 F6 F7 Total score
F1. Triggers   8 1.00 0.73* 0.57* 0.21* 0.37* 0.43* 0.27* 0.81* 0.59-0.81 0.80 0.76†
F2. Severity   9 1.00 0.68* 0.14* 0.44* 0.48* 0.23* 0.80* 0.54-0.80 0.77 0.84†
F3. Psychological distress   4 1.00 0.15* 0.52* 0.51* 0.21* 0.76* 0.47-0.68 0.83 0.73†
F4. Coping Strategies   9 1.00 0.11* 0.03 0.45* 0.50* 0.22-0.52 0.77 0.54‡
F5. Functioning impairments   6 1.00 0.44* 0.16* 0.66* 0.43-0.52 0.82 0.67‡
F6. Insight   3 1.00 0.16* 0.58* 0.49-0.60 0.87 0.80†
F7. Reassurance   3 1.00 0.49* 0.59-0.84 0.84 0.80†
Total score 42 1.00 0.22-0.80 0.85 0.90†
K-FCRI = Korean version of Fear of Cancer Recurrence Inventory, ICC = intra-class correlation coefficient.
*P < 0.00625 (Bonferroni correction applied); †P < 0.001; ‡P < 0.05.
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there was no significant correlation between the total summary 
score of K-FCRI with the depression category of HADS. Total 
summary score of K-FCRI was positively correlated with total 
score of FSS. We presented K-FCRI in Supplementary Table 2.
DISCUSSION
In this comprehensive validation study, we demonstrated a cross-
cultural equivalence and good psychometric properties of the 
K-FCRI, supporting that the K-FCRI is useful as a multi-dimen-
sional instrument for assessing FCR of Korean cancer survivors. 
The distribution of mean score of K-FCRI in our study showed 
similar distributions for overall scales and subscales to those of 
the original French version (8) or the English version (2). The 
order of subscales by mean score in this study was also very sim-
ilar to that of the original version of FCRI.
 We obtained acceptable level of Cronbach’s alpha (0.85) and 
corrected item-total correlation (0.22–0.80) for K-FCRI, although 
our estimates were slight lower than those obtained in the study 
for the original French-Canadian version (Cronbach’s alpha: 
0.95, item-total correlation: 0.26–0.82) (8). CFA showed that all 
goodness of fit indices of the K-FCRI met the required level of 
model fitness except for NNFI. The K-FCRI model fit was satis-
factorily improved by fixing nine covariance parameters, although 
items 13 (“I believe that I am cured and that the cancer will not 
come back”) and 14 (“In your opinion, are you at risk of having 
a cancer recurrence?”) among the nine covariance parameters 
found in the study of Lebel et al. (2) were replaced by items 15 
(“How often do you think about the possibility of cancer recur-
rence?”) and 16 (“How much time per day do you spend think-
ing about the possibility of cancer recurrence? “). These results 
confirmed the strong structure of FCRI even in a population 
with different language and culture. However, the slightly dif-
ferent finding regarding covariance parameters suggests that 
there might be redundancy among contents. Nevertheless, good 
construct validity of the K-FCRI assessed by convergent validity 
and concurrent criterion validity compensate the insufficient 
factorial analysis results, supporting that the K-FCRI is a useful-
ness tool to assess complex and multidimensional natures of 
FCR of Korean cancer survivors. Compared to the findings ob-
served in the study with the original version FCRI in French-Ca-
nadian or English speaking population (0.26–0.82), each item 
of K-FCRI subscales showed similar levels of correlation (0.22–
0.80) with total FCRI in Korean survivors (8). In general, each 
subscale of K-FCRI showed slightly weaker but similar correla-
tion with total K-FCRI score than the correlations found in the 
original version of FCRI study.
 However, the correlation between ‘coping strategies’ subscale 
and total FCRI was substantially different between the K-FCRI 
(r = 0.50) and the original French-Canadian version of FCRI 
(r = 0.74). In accordance with this, ‘coping measurement’ of 
FoP-Q had a weak correlation (r = 0.30) with the total score of 
FCRI in a Korean study (14). These findings indicate that coping 
strategies of Korean people might not have a close relation with 
fear of the disease. In addition, given the findings from a cross-
cultural study showing that Korean cancer patients have worse 
health related quality of life with depressive coping than Ger-
man or Japanese patients (24), it might be more difficult for Ko-
rean cancer patients to acquire adequate coping strategy for 
their FCR.
 We evaluated the correlations of the K-FCRI with several psy-
chometric measurement tools (EORTC QLQ-C30, HADS-anxi-
ety, and HADS-depression) as done for the development of the 
original French-Canadian FCRI (8). We found that the K-FCRI 
had substantial correlations with those tools except for HADS-
depression.
 The correlation coefficients between the subscales of EORTC 
QLQ-C30 and K-FCRI (−0.21 to −0.13) were similar but slightly 
lower than those observed in the original FCRI study (−0.36 to 
−0.20). In both studies, global quality of life, role functioning, 
and social functioning subscales of EORTC QLQ-C30 had high-
er correlations with FCRI than physical functioning or cognitive 
functioning. The original French-Canadian FCRI had signifi-
cant correlations with both HADS-anxiety and HADS-depres-
sion. It had moderate correlation with HADS-anxiety and low 
correlation with HADS-depression. In our study, the K-FCRI 
had no correlation with HADS-depression scale, while it had 
Table 5. Correlation between the K-FCRI and other Korean version tools measuring 
psychological distress
Tools
Score  
range
Mean score  
(SD)
Correlation coeffi-
cient (r) with FCRI 
FoP-Q
   Affective reaction 1–5 2.17 (0.80) 0.65†
   Partnership/family 1–5 2.16 (0.74) 0.56†
   Occupation 1–5 1.74 (0.83) 0.47†
   Loss of independence 1–5 1.83 (0.62) 0.57†
   Total* 1–20 7.73 (2.52) 0.73†
   Coping 1–5 3.01 (0.82) 0.30†
EORTC QLQ-C30
   Global health status 0–100 66.60 (18.8) −0.15†
   Physical functioning 0–100 78.90 (16.8) −0.13†
   Role functioning 0–100 83.50 (22.4) −0.21†
   Emotional functioning 0–100 76.90 (20.3) −0.31†
   Cognitive functioning 0–100 74.60 (20.1) −0.13†
   Social functioning 0–100 78.50 (24.6) −0.21†
HADS
   Anxiety 0–21 5.40 (2.9)  0.49†
   Depression  0–21 11.10 (3.3) 0.02
FSS, total  1–70 2.99 (1.7)  0.27†
K-FCRI = Korean version of Fear of Cancer Recurrence Inventory, SD = standard de-
viation, FCRI = Fear of Cancer Recurrence Inventory, FoP-Q = fear of progression 
questionnaire, EORTC QLQ-C30 = European Organization for Research and Treat-
ment of Cancer Quality of Life Questionnaire, HADS = Hospital Anxiety and Depres-
sion Scale, FSS = Fatigue Severity Score.
*Obtained by summation of mean values of four FoP-Q subscales except for coping 
scale. †P < 0.001.
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moderately high correlation with HADS-anxiety scale. This find-
ing is similar to the findings of Shim et al. (14). These findings 
suggest that the K-FCRI might be more useful for assessing anx-
iety than for assessing depressiveness in Korean people. In ad-
dition, we evaluated the correlation of K-FCRI with the Korean 
version of FoP, a validated tool for measuring the fear of disease 
progression in Korean cancer patients. In the previous study for 
112 Korean cancer patients, the FoP score of patients with re-
currence of cancer was significantly different from that of pa-
tients without recurrence (14). Therefore, the moderate to strong 
correlation of the K-FCRI with FoP seems to support the useful-
ness of K-FCRI as a valid tool for measuring the fear of cancer 
progression.
 The present study has some limitations. First, physicians and 
nurses were included as participants for cross-cultural valida-
tion because it was very hard to enroll bilingual (English–Kore-
an) cancer patients. Thus, medical directives’ experiences might 
have affected the translation. Second, FCR of people with ad-
vanced stage of cancer might not be adequately reflected to the 
translation process because a large portion of study participants 
has been diagnosed with relatively earlier stage of cancer. How-
ever, this issue does not seem to restrict the use of the K-FCRI 
given that the original French version of FCRI has been validat-
ed for use in cancer patients of a wide range of stages, including 
metastatic and recurrent cancers (8). Third, we could not estab-
lish the cut-off score for the K-FCRI to identify clinically signifi-
cant FCR. Therefore, further clinical studies are needed.
 In conclusion, this study confirmed that the K-FCRI could be 
used as a valid and reliable psychometric test to measure FCR 
of Korean cancers survivors with various cancer sites.
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Supplementary Table 1. Distribution of participants and non-participants
Items of participants
Participants 
(n = 447)
Non-participants 
(n = 156)
P value
Age 56.3 (10.3) 58.9 (10.4) 0.007
Time lapse since cancer diagnosis 5.99 (4.15) 5.97 (4.73) 0.953
Sex,_female 64.7 64.1 0.902
Cancer site < 0.001
   Stomach 39.0 28.8
   Breast 25.3 23.7
   Lung 9.4 12.2
   Thyroid 8.5 7.7
   Others 17.8 27.6
Surgery 96.1 92.8 0.102
Chemotherapy 41.5 48.0 0.170
Radiotherapy 37.3 38.7 0.770
Data were presented as mean (standard deviation) or percentage.
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Supplementary Table 2. K-FCRI 
암 진단을 받은 사람들은 대부분 정도의 차이는 있지만 암이 재발 할지도 모른다는 걱정을 합니다. 여기서 암의 재발은 기존 암이 다시 생기거나 진행하는 것을 의
미합니다. 
이 설문지는 암 경험자의 암 재발에 대한 두려움을 더 잘 이해하기 위해 개발되었습니다. 
다음 모든 항목에 대해 지난 한달 동안 귀하가 경험한 것과 가장 잘 일치하는 정도를 골라 해당 칸에 O표 해 주십시오.
 다음 상황은 암 재발 가능성에 대하여 생각하게 한다.
ⓞ 
전혀 그렇
지 않다
① 
드물게  
그렇다
②  
가끔  
그렇다
③  
대부분  
그렇다
④  
항상  
그렇다
  1. 암이나 질병에 대한 텔레비전 프로나 신문기사를 볼 때
  2. 담당 의사나 다른 의사에게 진료받을 때
  3. 병원에서 검사 받을 때 (예: 정기검진, 혈액검사, 방사선검사)
  4. 사람들과 암이나 질병에 대해 이야기할 때
  5. 아픈 사람을 보거나 아픈 사람에 대한 얘기를 들을 때
  6. 장례식장에 가거나, 신문에서 부고 기사를 읽을 때
  7. 몸 상태가 안 좋다고 느끼거나 아플 때
  8. 나는 대부분 암 재발 가능성을 생각하게 하는 상황이나 일을 피한다
ⓞ 
전혀 그렇
지 않다
① 
조금 
그렇다 
② 
다소 
그렇다
③ 
많이 
그렇다
④ 
매우 
그렇다
  9. 나는 암이 재발할까 봐 걱정되고 불안하다
10. 나는 암 재발이 두렵다
11. 나는 암 재발 가능성을 걱정하고 불안해하는 것이 당연하다고 생각한다
12.  암이 재발할 가능성을 생각할 때 다른 불쾌한 생각이나     이미지가 떠오른다(죽음, 고통, 
내 가족에게 미칠 영향 등)
13. 나는 완치되었고 암이 다시 생기지 않을 것이라고 믿는다
14. 스스로 생각하기에, 귀하의 암이 재발할 가능성이 있다고 생각합니까?
ⓞ 
전혀 생각 
안 한다
① 
한 달에 
몇 번
② 
일주일에 
몇 번
③ 
하루에  
몇 번
④ 
하루에도 
여러 번
15. 암이 재발할 가능성에 대해 얼마나 자주 생각 하십니까?
ⓞ 
생각하지 
않는다
① 
몇 초간 
생각한다
② 
몇 분간 
생각한다
③ 
몇 시간 
생각한다
④ 
여러시간 
생각한다
16. 암이 재발할 가능성에 대해 생각한다면 하루 중 얼마 동안 생각하십니까?
ⓞ 
생각 
안 했다
① 
몇 주간
② 
몇 달간 
③ 
몇 년간 
④ 
여러 해 
17. 암이 재발할 가능성에 대해 얼마나 오랫동안 생각했습니까?
암이 재발할 가능성에 대해 생각할 때 다음과 같은 감정을 느낍니까? 
ⓞ 
전혀 그렇
지 않다
① 
조금 
그렇다
② 
다소 
그렇다
③ 
많이 
그렇다
④ 
매우 
그렇다
18. 걱정, 두려움, 불안
19. 슬픔, 의기소침, 실망
20. 좌절, 화, 분노
21. 무력함, 체념
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암이 재발할 가능성에 대한 걱정과 두려움 때문에 다음 일들에 지장이 있습니까? 
ⓞ 
전혀 그렇
지 않다
① 
조금 
그렇다
② 
다소 
그렇다
③ 
많이 
그렇다 
④ 
매우 
그렇다
22. 사회활동이나 여가활동 (예: 야유회, 스포츠활동, 여행)
23. 직업 활동이나 일상 생활
24. 배우자(이성친구), 가족, 친한 사람과의 관계
25. 장래 계획을 세우거나 인생 목표를 정하는 것
26. 마음이나 감정 상태
27. 전반적인 삶의 질
28. 내가 암 재발 가능성에 대해 지나치게 걱정하고 있다고 느낀다
29. 다른 사람들은 내가 암 재발에 대해 지나치게 걱정하고 있다고 생각한다
30. 다른 암환자에 비해 내가 암 재발 가능성에 대해 더 많이 걱정하고 있다고 생각한다
암이 재발할 가능성에 대해 생각할 때는 스스로를 안심시키기 위해 다음과 같은 방법을 사용
한다.
ⓞ 
전혀 그렇
지 않다
① 
드물게 
그렇다 
② 
가끔 
그렇다 
③ 
대부분 
그렇다 
④ 
항상 
그렇다
31. 담당 의사나 다른 의료인과 상담한다
32. 병원에 가서 검사를 받아본다
33. 암 관련 신체 증상이 있는지 스스로 살펴본다
34. 관심을 다른 데로 분산시키려 노력한다 (예: 텔레비전 시청, 독서, 일하기)
35. 암 재발에 대해 생각하지 않고 내 마음에서 멀리하려고 노력한다
36. 기도나 명상, 이완요법을 한다.
37. 다 잘 될 것이라고 스스로 위안하거나 긍정적으로 생각한다
38. 다른 사람과 암 재발에 대해 이야기한다
39. 이성적으로 상황을 이해하고 대처하려고 노력한다
40. 해결책을 찾으려고 한다
41. 즐거운 생각으로 대체하려고 노력한다
42. 나 스스로에게 “그런 생각을 멈추자”라고 말한다
위와 같은 방법들을 사용하면 안심하게 됩니까?
